March 01, 2011
Daliresp Approved for COPD
Daliresp is a selective phosphodiesterase type 4 (PDE4) inhibitor thought to exert its therapeutic effect via increased intracellular cyclic AMP in lung cells. Daliresp will be available in the second quarter of 2011.
For more information call (800) 678-1605 ext. 66297 or visit www.daliresp.com.